Imatinib methanesulfonate reduces hippocampal amyloid-beta and restores cognitive function following repeated endotoxin exposure

Brain, Behavior, and Immunity

Volumn 33, Issue , 2013, Pages 24-28

  Weintraub, Marielle K ^a   Bisson, Courtney M ^a   Nouri, Jessica N ^a   Vinson, Benjamin T ^a   Eimerbrink, Micah J ^a   Kranjac, Dinko ^a   Boehm, Gary W ^a   Chumley, Michael J ^a  

^a TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Cytokines; Lipopolysaccharide; Memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ENDOTOXIN; GAMMA SECRETASE; IMATINIB; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; COGNITIVE DEFECT; CONDITIONING; EXPOSURE; FEAR; HIPPOCAMPUS; INFLAMMATION; LEARNING DISORDER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; AMYLOID-BETA; CYTOKINES; LIPOPOLYSACCHARIDE; MEMORY;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BENZAMIDES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTOXINS; HIPPOCAMPUS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PIPERAZINES; PYRIMIDINES;

EID: 84883750073     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.05.002     Document Type: Article

References (20)

1. Cras P., Smith M.A., Richey P.L., Siedlak S.L., Mulvihill P., Perry G. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol. 1995, 89(4):291-295.
2. Cunningham C., Campion S., Lunnon K., Murray C.L., Woods J.F., Deacon R.M., Rawlins J.N., Perry V.H. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol. Psychiatry 2009, 65(4):304-312.
3. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
4. He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J., Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010, 467(7311):95-98.
5. Heneka M.T., O'Banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184(1-2):69-91.
6. Jaeger L.B., Dohgu S., Sultana R., Lynch J.L., Owen J.B., Erickson M.A., Shah G.N., Price T.O., Fleegal-Demotta M.A., Butterfield D.A., et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav. Immun. 2009, 23(4):507-517.
7. Kahn M.S., Kranjac D., Alonzo C.A., Haase J.H., Cedillos R.O., McLinden K.A., Boehm G.W., Chumley M.J. Prolonged elevation in hippocampal Abeta and cognitive deficits following repeated endotoxin exposure in the mouse. Behav. Brain Res. 2012, 229(1):176-184.
8. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., LaFerla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25(39):8843-8853.
9. Kranjac D., McLinden K.A., Deodati L.E., Papini M.R., Chumley M.J., Boehm G.W. Peripheral bacterial endotoxin administration triggers both memory consolidation and reconsolidation deficits in mice. Brain Behav. Immun. 2012, 26(1):109-121.
10. Lee J.W., Lee Y.K., Yuk D.Y., Choi D.Y., Ban S.B., Oh K.W., Hong J.T. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J. Neuroinflammation 2008, 5:37.
11. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430(7000):631-639.
12. McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., Das P., Golde T.E., LaFerla F.M., Oddo S., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 2009, 34(1):163-177.
13. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18(3):315-321.
14. Mucke L., Selkoe D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012, 2(7):a006338.
15. Murphy M., LeVine H. Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 2010, 19(1):311-323.
16. Sutcliffe J.G., Hedlund P.B., Thomas E.A., Bloom F.E., Hilbush B.S. Peripheral reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: implications for Alzheimer's disease. J. Neurosci. Res. 2011, 89(6):808-814.
17. Takayama N., Sato N., O'Brien S.G., Ikeda Y., Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br. J. Haematol. 2002, 119(1):106-108.
18. Terry R.D. Alzheimer's disease and the aging brain. J. Geriatr. Psychiatry Neurol. 2006, 19(3):125-128.
19. Williams R.T., den Besten W., Sherr C.J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+. Arf-null lymphoblastic leukemia. Genes Dev. 2007, 21(18):2283-2287.
20. Wolff N.C., Richardson J.A., Egorin M., Ilaria R.L. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003, 101(12):5010-5013.